US › Healthcare

Definium Therapeutics, Inc. (DFTX)

US · Healthcare · Biotechnology

$42.32+1.27%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-77.1M
Profit YoY
-230.2%
EPS
$-0.50
EPS estimate
$-0.55

EPS came in at -0.50 against a street estimate of -0.55 — a beat of 9.1%.

Key statistics

Market cap
$5.78B
Forward P/E
0.0
P/B
20.72
Book value
$2.68
EPS (TTM)
$-2.50
52-week high
$49.20
52-week low
$8.70
50-day MA
$35.31
200-day MA
$21.11
Beta
2.21

Analyst view

with an average price target of $60.00.

Shareholding

Insiders
1.33%
Institutions
74.70%

Largest institutional holders

FundStake
BlackRock Inc6.39%
Driehaus Capital Management LLC4.45%
venBio Select Advisor LLC3.77%
HHG PLC2.68%
Deep Track Capital, LP2.26%
Geode Capital Management, LLC1.88%
State Street Corp1.86%
Octagon Capital Advisors LP1.84%

Recent filings & reports

DocumentDate
Material agreement · Q2 20262026-06-24
Reg FD disclosure · Q2 20262026-06-22
Board / officer change · Q2 20262026-06-12
Company announcement · Q2 20262026-05-19
Quarterly report · Q1 20262026-05-07
Proxy statement · Q2 20262026-04-27
Annual report FY20252026-02-26
Quarterly report · Q3 20252025-11-06

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Definium Therapeutics, Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.